We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Wall Street's Insights Into Key Metrics Ahead of Globus Medical (GMED) Q4 Earnings
Read MoreHide Full Article
Wall Street analysts forecast that Globus Medical (GMED - Free Report) will report quarterly earnings of $1.06 per share in its upcoming release, pointing to a year-over-year increase of 26.2%. It is anticipated that revenues will amount to $787.85 million, exhibiting an increase of 19.9% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some Globus Medical metrics that Wall Street analysts commonly model and monitor.
It is projected by analysts that the 'Net Sales by Product Category- Enabling Technologies' will reach $33.70 million. The estimate indicates a change of -28.2% from the prior-year quarter.
The average prediction of analysts places 'Net Sales by Product Category- Musculoskeletal Solutions' at $735.95 million. The estimate suggests a change of +20.6% year over year.
The collective assessment of analysts points to an estimated 'Geographic Revenues- International' of $147.72 million. The estimate suggests a change of +9.1% year over year.
The consensus among analysts is that 'Geographic Revenues- United States' will reach $621.92 million. The estimate points to a change of +19.2% from the year-ago quarter.
Globus Medical shares have witnessed a change of -4.3% in the past month, in contrast to the Zacks S&P 500 composite's -0.8% move. With a Zacks Rank #2 (Buy), GMED is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Wall Street's Insights Into Key Metrics Ahead of Globus Medical (GMED) Q4 Earnings
Wall Street analysts forecast that Globus Medical (GMED - Free Report) will report quarterly earnings of $1.06 per share in its upcoming release, pointing to a year-over-year increase of 26.2%. It is anticipated that revenues will amount to $787.85 million, exhibiting an increase of 19.9% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some Globus Medical metrics that Wall Street analysts commonly model and monitor.
It is projected by analysts that the 'Net Sales by Product Category- Enabling Technologies' will reach $33.70 million. The estimate indicates a change of -28.2% from the prior-year quarter.
The average prediction of analysts places 'Net Sales by Product Category- Musculoskeletal Solutions' at $735.95 million. The estimate suggests a change of +20.6% year over year.
The collective assessment of analysts points to an estimated 'Geographic Revenues- International' of $147.72 million. The estimate suggests a change of +9.1% year over year.
The consensus among analysts is that 'Geographic Revenues- United States' will reach $621.92 million. The estimate points to a change of +19.2% from the year-ago quarter.
View all Key Company Metrics for Globus Medical here>>>Globus Medical shares have witnessed a change of -4.3% in the past month, in contrast to the Zacks S&P 500 composite's -0.8% move. With a Zacks Rank #2 (Buy), GMED is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .